Open AccessThe Prevalence of Metabolic Syndrome of Patients on Treatment with Haloperidol and Risperidone or Olanzapine
Author(s) -
Velumani Suresh,
Jitendra D. Lakhani,
Rakesh Shah,
Lakhan Kataria,
R Balaraman
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i44a32618
Subject(s) - olanzapine , risperidone , haloperidol , antipsychotic , metabolic syndrome , medicine , schizophrenia (object oriented programming) , dopamine antagonist , lipid profile , body mass index , psychiatry , obesity , cholesterol , dopamine
Background: The background of the work stems from the observation due to the prevalence of antipsychotic drugs in causing metabolic disorder. The metabolic disorder is one of the major concern of antipsychotic drugs for schizophrenic patients. The present study is mainly aimed to establish the role of haloperidol and risperidone or olanzapine in causing metabolic syndrome of schizophrenic patients.
Methods: Sixty-four schizophrenic patients were divided into two groups. First and second group received haloperidol and risperidone or olanzapine respectively for three months. Body mass index, random blood sugar and lipid profile were investigated before and after the treatment.
Results: Both groups of schizophrenic patients have shown a significant increase in the BMI, random blood sugar and lipid profile indicating a propensity to cause metabolic disorder.
Conclusion: From the present study it is concluded that there is a high prevalence of metabolic disorder those who received antipsychotic drugs like haloperidol and risperidone or olanzapine.